Answers are grounded in this paper and cite their sources.
Intratumoral (IT) injections of Glucopyranosyl lipid A (G100), a synthetic toll-like receptor 4 (TLR4) agonist formulated in a stable emulsion, resulted in T-cell inflammation of the tumor microenvironment, systemic tumor-specific CD4 and CD8 T-cell responses, and complete cure of mice with large established A20 lymphomas, including cure of 50% of animals in a bilateral tumor model in which only one lesion was injected. Surviving mice resisted a secondary challenge and depletion of CD8 T-cells, but not CD4 or NK cells, abrogated the anti-tumor effect. Unexpectedly, TLR4 knock-out in A20 cells rendered tumors completely non-responsive to G100. As shown by genotyping and phenotyping analysis, G100 strongly activated antigen presentation functions in A20 cells in vitro and in vivo and induced their apoptosis in a dose dependent manner. Similarly, the TLR4 positive human mantle cell lymphoma line Mino showed in vitro activation with G100 that was blocked with an anti-TLR4 antibody. In the A20 model, direct activation of immune functions in B-lymphoma cells with G100 is sufficient to induce protective anti-tumor CD8 T-cell responses and TLR4 expressing human B-cell lymphomas may be amenable to this therapy as well.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: